On this page
MECP2 duplication syndrome is an X-linked neurodevelopmental condition caused by increased dosage of MECP2, usually within a larger Xq28 duplication. Published cohorts mainly describe boys and men with hypotonia, developmental disability, limited speech, progressive spasticity, feeding or gastrointestinal problems, recurrent respiratory infections, and variable epilepsy. Girls, women, and people of any gender can also have clinically important effects. Phenotype depends partly on the number of X chromosomes, X-inactivation, duplication structure, mosaicism, and other genes included; sex or gender alone does not predict severity. See GeneReviews.
Urgent and procedure-related safety
Seek urgent assessment for breathing difficulty, blue or gray color, pauses in breathing, inability to clear secretions, repeated choking, dehydration, a first or prolonged seizure, or failure to return toward the person's usual alertness. Fever with fast or labored breathing, new oxygen need, wet breathing, or marked lethargy may indicate pneumonia or another significant infection.
Respiratory illness may be compounded by hypotonia, weak cough, aspiration, reflux, scoliosis, sleep-disordered breathing, or immune differences. A written illness plan should describe the person's respiratory baseline, airway-clearance supports, feeding route, seizure plan, and thresholds for escalation.
Before sedation, surgery, or a change in care setting, share the person's respiratory and infection history, aspiration and reflux risk, sleep and airway needs, seizure medicines, positioning, and communication access. A new loss of skill or sudden behavior change also warrants evaluation for seizures, pain, constipation, infection, medication effects, sleep disruption, and access failure.
Quick reference
| Topic | Condition-specific guidance |
|---|---|
| Cause | Duplication containing MECP2 on Xq28; size and neighboring genes vary |
| Sex and phenotype | People with one X are often more consistently affected; people with more than one X have a wider range related partly to X-inactivation and rearrangement structure |
| Diagnosis | Copy-number testing that demonstrates an MECP2-containing duplication, followed by characterization and family testing as indicated |
| Major health needs | Respiratory infection and aspiration risk, feeding and gastrointestinal health, seizures, tone, mobility, and development |
| Communication | Spoken output may be limited; comprehension, preferences, social intent, hearing, vision, and motor access need direct assessment |
| AAC | Early and multimodal, with access chosen through individual trials rather than sex or diagnosis |
Recognition and diagnosis
Possible findings include infantile hypotonia, delayed motor development, limited or absent speech, feeding difficulty, reflux or constipation, recurrent respiratory infections, seizures, increasing lower-limb spasticity, scoliosis or contracture, movement differences, and autistic or anxiety-related traits. The pattern is not specific enough for diagnosis without genetic testing.
Chromosomal microarray often detects the duplication and shows its approximate boundaries. Targeted copy-number testing may identify MECP2 dosage but provide less information about size or neighboring genes. Genetics review may add chromosome or other studies to identify an insertion or translocation, assess X-inactivation when informative, test parents, and provide family-specific counseling.
People with two X chromosomes may be asymptomatic, mildly affected, or have a phenotype similar to more commonly reported cases. They should not be described automatically as unaffected carriers. The genetic result, symptoms, and personal identity should each be documented precisely.
Coordinated care
Care may involve genetics, primary care, neurology, pulmonology, immunology, gastroenterology, nutrition, rehabilitation, orthopedics, sleep medicine, physical and occupational therapy, and speech-language pathology. Review should address respiratory infections, cough and secretion clearance, sleep breathing, swallowing and aspiration, reflux and constipation, nutrition, seizures, tone, pain, hip and spine health, mobility, hearing, vision, behavior, and participation.
Treatment is directed to the person's manifestations. Antibiotics, airway clearance, respiratory support, seizure medicines, tone management, orthopedic care, nutrition support, and therapy require individualized clinical decisions. Investigational molecular approaches should not be presented as established care.
Speech, language, and interaction
Speech can be markedly limited by language, motor planning, tone, breath support, hearing, movement, and recurrent illness. Spoken output is not a valid measure of comprehension, social interest, pain, or decision-making ability. Assessment should include receptive and expressive language, hearing, vision, gesture, literacy, motor access, and communication across familiar and unfamiliar partners.
Provide an accessible way to report breathing, pain, constipation, seizures, fatigue, refusal, consent, and preferences. Address the person directly, allow response time, model communication without requiring imitation, and confirm intended meaning.
Feeding and swallowing
Feeding concerns may involve dysphagia, aspiration, reflux, constipation, reduced oral coordination, posture, fatigue, and respiratory illness. Possible warning signs include coughing or choking, wet or changed voice, congestion with meals, recurrent chest illness, long meals, distress, poor intake, or growth and hydration concerns. Aspiration may occur without an obvious cough.
Clinical feeding and swallowing assessment should consider breathing, secretion management, posture, oral movement and sensation, endurance, gastrointestinal symptoms, nutrition, and preferences. Instrumental assessment may be indicated when swallowing physiology or aspiration risk is unclear. Pacing, positioning, texture, reflux treatment, airway clearance, and oral or tube-feeding decisions require individualized and coordinated planning.
AAC and access planning
AAC should be considered early when speech does not meet communication needs. There are no cognitive, motor, behavioral, or age prerequisites. A multimodal plan may combine vocalization, facial expression, gesture, sign, objects, pictures, writing, partner strategies, and speech-generating technology.
Feature matching should assess language and literacy, vision, hearing, hand use, spasticity, involuntary movement, seating, fatigue, respiratory equipment, and settings. Touch, adapted direct selection, switches, eye tracking, and partner-assisted scanning are options to trial, not syndrome-based prescriptions. Include health, consent, relationships, education, leisure, and emergency vocabulary; train partners; and maintain a portable low-tech backup. See the AAC assessment and acquisition guide and ASHA AAC Practice Portal.
Participation and prognosis
Education and adult services should be based on observed strengths, health, communication, movement, and goals. Supports may include accessible instruction, communication partners, rest after illness, positioning, alternative task access, and explicit respiratory and seizure plans.
Outcome varies with duplication structure, X-inactivation, infections, epilepsy, respiratory and feeding health, mobility, communication access, environment, and support. Neither sex nor duplication size alone gives an individual prognosis. Reassessment is appropriate after illness, a change in skills, new seizures, loss of communication access, or transition in care.